Federal law requires Medicare Part D prescription drug plans to offer medication therapy management (MTM) programs to help targeted enrollees avoid drug-related problems and optimize medication benefits. In 2006, such programs were hailed as a "win-win" proposition for plans, pharmacists, and beneficiaries. However, six years later, MTM participation is lower than predicted, and it is still not possible to evaluate whether Part D MTM programs are working as intended. This has frustrated Part D plan sponsors and the federal government alike, especially considering MTM's success in Medicaid and in the private sector. This Insight on the Issues proposes policy options for demonstrating and increasing MTM's effectiveness within Part D.
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)